43064-12-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride is used as a pharmaceutical intermediate for the development of drugs targeting poly(ADP-ribose) polymerase-1 (PARP-1). Its presence in benzamide analogs improves their inhibitory potential against PARP-1, making it a valuable component in the creation of therapeutic agents for treating various diseases, including cancer.
Used in Research and Development:
In the field of scientific research, 4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride serves as a key compound for studying the interactions between PARP-1 and benzamide derivatives. This research can lead to a better understanding of the enzyme's role in disease processes and the development of more effective treatments.
Used in Drug Synthesis:
4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride is utilized in the synthesis of novel drugs that aim to modulate the activity of PARP-1. Its incorporation into drug molecules can enhance their efficacy and selectivity, potentially leading to improved therapeutic outcomes for patients.
Overall, 4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride plays a crucial role in the pharmaceutical and research industries, contributing to the advancement of treatments for various diseases and the deepening of our understanding of PARP-1's biological functions.

Upstream product

• 108-86-1 bromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 38025-45-5 1-benzyl-4-phenyl-1,2,3,6-tetrahydro-pyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 21820-81-5 5-[2-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-ethyl]-oxazolidin-2-one 
• 21820-82-6 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-ethyl]-oxazolidin-2-one 
• 143682-24-0 2-(1H-Indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-ethanone 
• 143682-29-5 4-(2-Methyl-1H-indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-butan-1-one 
• 143682-26-2 5-(1H-Indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-pentan-1-one 
• 143682-30-8 4-(5-Fluoro-1H-indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-butan-1-one 
• 143682-31-9 4-(5-Chloro-1H-indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-butan-1-one 
• 143682-27-3 6-(1H-Indol-3-yl)-1-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-hexan-1-one 
• 165590-70-5 1,2,3,6-tetrahydro-1-<(3-oxocyclohexyl)carbonyl>-4-phenylpyridine 
• 143017-49-6 1-(2,2-diethoxyethyl)-4-phenyl-1,2,5,6-tetrahydropyridine 
• 201608-41-5 2a-[4-(4-phenyl-1,2,3,6-tetrahydropyridyl)butyl]-2a,3,4,5-tetrahydrobenz[cd]indole-2(1H)-one 
• 213923-73-0 2-chloro-4-(4-phenyl-1,2,3,6-tetrahydropyridino)-6-methylpyrimidine 

Relevant academic research and scientific papers

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.